Slide 1: Bora Pharmaceuticals Investor Conference
Bora Pharmaceuticals Investor Conference May 13th .2021
Slide 2: Table of Contents
Company Introduction Company fact sheet, leadership team, milestones 01 Operation Highlights 02 CDMO operation: facilities, CDMO services Commercial operation 03 Financial Results Finansial results, successful M&A model Table of Contents 04 Bora’s Growth Strategy Investor Conference 05 Future Outloo
Slide 3: Bora by the numbers
500 Million USD Market Cap 950+ Employees Bora by the 3 Manufacturing Sites 100+ Export Countries numbers 1.2B+ Annual Units Produced 98% On-Time Delivery 3 Completed M&A in 5 years
Slide 4: Bora's Companies Portfolio
Bora’s Companies Portfolio 保瑞集團 Bora Group Bora Pharmaceuticals Bora Pharmaceuticals Bora Pharmaceuticals Bora 聯邦化學製藥股份 宇泰欣藥業 (Tainan Facility) Laboratories(Zhunan) USA (USA) Pharmaceuticals 有限公司 Services (Canada) Global CDMO Operations Commercial Operations
Slide 5: Leadership team
專業領導團隊 Leadership team 陳世民 盛保熙 張振棠 王錦菊 Andrew Ehrat 集團副總經理 董事長兼執行長 總經理兼廠長 財務長 加拿大廠總經理 兼研發長 藥業25年豐富經驗 藥品製造27年 科技與生技產業 藥業經驗24年 25 製藥業經驗 以上經驗 財務領域工作超 保瑞集團創辦人 過25年 和安行事業開發部 曾服務於Dow 保瑞集團益邦製藥 經理 Chemical, P&G, 代理lundbeck 與 Kiehl’s 等品牌進 總經理 專長於成本管理、 and GSK. 丹麥H.Lundbeck 入亞洲市場 上市櫃法規、併 A/S 產品經理 輝瑞大藥廠廠長 購、投資
Slide 6: Bora Milestones
Bora Milestones 2007 2017 2020 Bora Pharmaceuticals Bora Initial Public Bora Acquires GSK is Established as a Offering (IPO) on the Mississauga Facility Development Scale Taipei Stock Exchange and long-term supply 1972 CDMO 2014 production agreement Bora Acquires Union Hoan Pharmaceuticals Pharmaceu
Slide 7: Milestones 2020
Milestones 2020
Slide 8: KCl shipped to US June 2020
KCl 2020年6月出貨美國 2020年9月快速成長一百強
Slide 9: Operational Highlight
Operational Highlight
Slide 10: What are CDMO Services?
Before we start…. What are CDMO Services?
Slide 11: Bora CDMO Services
保瑞國際委託研發暨生產服務CDMO Services 委 託 開 發 (CDO) 配方設計 產品檢驗 試製放大 查驗登記 商品開發 1.新成分劑型 1.委託檢驗 1.製程參數 1.查登資料建立 開發 2.委託檢驗 建立 2.國際法規諮詢 2.新劑型開發 方法開發 2.製程最佳化 Bora Pharamceuticals 一站式 CDMO國際委託研發暨生產服務 高品質 特殊劑型 量產放大 藥品包裝 商品上市 生產 1. 長效釋放 1. US FDA 1.製程參數 1.序列化包裝 2. 多單位釋放 2. EMA 變更與建立 2.自動化包裝 3. PMDA 2.製程最佳化 委 託 製 造 (CMO)
Slide 12: CDMO Market by Region
CDMO Market by Region According to PwC report, the Asia-Pacific region, particular China and India, has been the leading growth market in the CDMO industry.
Slide 13: CDMO Major Leading Players
CDMO Major Leading Players Company Headquarters Area of Business Sales Revenue Lonza Switzerland Biopharmaceuticals, organic and fine chemicals, chemical synthesis US$5bn equipment, custom manufacturing of chemicals and related products. Supply Moderna and AZ COVID-19 vaccines Catalent USA Provides
Slide 14: Zhunan Facility
Zhunan Facility 36,133 Sq. Meters USFDA, MHRA and TFDA Approved • Built by Impax - US • High quality standards Dosage Forms: Tablets, Capsules, Extended Release 2 billion units of solid-dosage form (IR and ER) Bottle Packaging and Serialization Export Destination: USA & EU 14
Slide 15: Tainan Facility
Tainan Facility 24,000 Sq. Meters PIC/S & GCC certified Built by Eisai - Japan Dosage Form Tablets, Capsules, Granules 700 million units of solid-dosage form Export Destination: Southeast Asia, Mid-south Asia, Middle East Packaging Lines: Blisters, granules, sachets, tablets/capsules, soft capsules
Slide 16: Mississauga Facility (formerly GSK)
Mississauga Facility (formerly GSK) 179,720 Sq. Meters Dosage Form Export Destination • Semi-Solids • North America • Liquids • South America • Tablets • Asia • Capsules • Russia • Middle East Certifications • USFDA • Health Canada • EMA • PMDA • MORE • Other worldwide agencies 16
Slide 17: Video Link
Video Link: https://www.youtube.com/watch?v=dL4YrNC9jbA 17
Slide 18: Mississauga Facility Performance Our Strengths
Mississauga Facility Performance Our Strengths Mississauga site Supply 100 Chain 3600萬 79% Values Distribute 加幣 2020 Market Cover NA Global Voltaren Markets 順利完成接廠、出貨，並通過加拿大衛生部查核 leading 2018 美國單一市 CDMO 建立 場成長率 partner Voltaren 79%。 GSK訂單需求成長：美國FDA於2020年將 全新生產線 Voltaren 2020轉為指示用藥，當年度美國單一 市場成長率79%，並
Slide 19: Commercial Operation
Commercial Operation
Slide 20: Company Products Status and Highlights
藥品代理經銷業務持續成長 Company Products Status and Highlights • 2021 Q2 健保價申請中 瑞多寧 • 取得多國經銷權 帕金森氏症 • 數家醫學中心引進 • 帕金森氏症病友支持計畫 • 搶佔10億台灣帕金森氏症市場 • 已取得台灣藥證 康是鉀 • 健保價申覆中 持續性藥效錠 • 台灣食藥署歸入必須藥品清單 低血鉀症 • 目前台灣市面上無錠劑藥證 • 美國處方數排名第37之藥品 • 保瑞配合特定醫院專案製造 • 每年雙位數成長 • 藥效緩和; 副作用輕微 戀多眠 • 保瑞代理經銷長達十年穩定產品 失眠 • 敏特思銷售業績持續成長 • 憶必佳保瑞代理經
Slide 21: Commercialization through complete Distribution Channel Coverage
Commercialization through complete Distribution Channel Coverage Hospitals • Medical Center Distribution • Regional Hospital Channel Increase • Foundation Hospital Clinics • General Physician • Area Distributor Pharmacies • BNHI Pharma • CVS • Chain Store
Slide 22: Chocola ,
Chocola , BB ChocolaBB ) HE $3 Hs 0 2 IB 7 5 i% \ HEARBRHH/ BARE BRoohe AS — IAIABR ‘Tor | ay ~ [meer na BOOST bord ig te 45 su BER RRB : 2 ih BOIRON SORREeR
Slide 23: REET AG eM O IO
REET AG eM O IO Eiak teeeay RRHED! €& FARRD | — RB E — #548 15 7 eh Etak*t#@o) | Rib MRa - i Mit RM on Camm | 7k * WA: te! nea te an RAP YPHBUCATL— a0 7 72h HOTTA NETOMONMEBDITIBVREA, > * (Aare 1O0OE LEO ATP OBE P| ae Ricks 300 @ ARR ed © 49.5;ii0:IIL-C TAB eee er : N A) ex || RE ae 6B ie ifs aes 4B
Slide 24: Financial Results
Sl contributing to Better Health All 1@{@)(@ Over the World ——_ ste = on Line * a a a eS
Slide 25: Consolidated Financial Statement
Consolidated Financial Statement $NTD Million 2020 2019 2020 2021 Q1 Year Variation Amount % Amount % % Amount Revenue 1,529 100% 1,800 100% +18% 1,367 Gross Profit 643 42% 704 39% +9% 602 Operating Expense 298 20% 478 26% +60% 152 Net Operating Income 344 22% 226 13% -34% 450 Non-operating Income a
Slide 26: Monthly Revenue
Monthly Revenue 600 544 500 428 414 395 400 357 300 200 147 149 152 133 118 121 124 130 119 132 108 100 0 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2020年 2021年
Slide 27: Financial Performance
Financial Performance 1800 1800 1600 1529 1400 1372 1200 1367 1000 Revenue 800 600 643 704 358 445 445 Gross Profit 400 578 126 344 602 200 19 187 15 305 226 450 0 334 Net Operating Income 2017 2018 2019 Net Profit 2020 2021 Q1
Slide 28: Financial Performance
Financial Performance 7 6 Bora Dividends 6 5 5 4.5 4 3 2 1 0.8 1 0.5 0 2016 2017 2018 2019 2020 2021 2021 Payout A POWERFUL VALUE-CREATING Cash Dividends NT$ 2 BUSINESS MODEL Stock Dividends NT$ 2.5
Slide 29: Bora's Growth Strategy
Bora’s Growth Strategy
Slide 30: Market Trends
Market Trends Growing Demand for Pharmaceutical Products Increasing Pressure to Reduce Cost Burden Improving Technical Capabilities & Expertise of CDMOs Source: https://www.fortunebusinessinsights.com/contract-development-and-manufacturing-organization-cdmo-outsourcing-market-102502
Slide 31: CDMO Market
CDMO MARKET $130.8 $278.98 BILLION BILLION 2018 2026 CAGR 10.0% 2019-2026 Source: https://www.fortunebusinessinsights.com/contract-development-and-manufacturing-organization-cdmo-outsourcing-market-102502
Slide 32: Bora's Industry Integration Plan
Bora’s Industry Integration Plan Current Capabilities Future growth targets
Slide 33: Bora's Two-Pronged Growth Strategy
Bora’s Two-Pronged Growth Strategy Organic Growth • High Focus on new business with continued investment Marketing and Sales. • Build strong pipeline of development project. • Invest in new technologies to increase commercial scale efficiency. • Invest in new production lines and formulations to inc
Slide 34: Annual Revenue Growth
近年營收趨勢Annual Revenue Growth Organic Growth Unit: NT$ 100M 25 17.9 Inorganic Growth 20 15.29 13.72 15 Organic Growth 10 3.58 2.83 5.41 2.18 2.38 5 3.94 2.64 2.94 2.24 2.24 2.33 0 2014 2015 2016 2017 2018 2019 2020 Share Capital Revenue
Slide 35: Bora Market Cap
Bora Market Cap 14 12 12 10.63 10 8 5.91 6 Market Cap 3.18 multiplied by 10x 4 since IPO! 2 1.2 0 2013 2014 2017 2018 2019 2020 2021 Q1 35
Slide 36: Bora's Dedication to Become Global
Bora’s Dedication to Become Global Capture Global Markets • Strategic M&A within US, EU, and Continuous Expansion Asia • Launch New • Increase International Products and CDMO partners Dosage Form Stable Profitability • Pharmaceutical • Expand Pharma CDMO and CHC products • Pharmaceutical/ Health Pro
Slide 37: Bora's Win-win Strategy
Bora’s Win-win Strategy雙贏策略與成功模式 取得生產藥 Win-Win 品之區域經 Win-Win 銷代理權 • 成為原廠的代工合作夥伴 • 建立穩定代工訂單 • 精準選擇標的 • 透過合作關係取得所生產 • 國際併購經驗 • 原廠釋出廠房 產品之區域經銷代理權 取得 原廠代 創造規模經濟，提升毛利 工合約 擴展產品組合，提升服務與品 成功併購 牌價值 拓展全球供應鏈
Slide 38: Future Outlook
Contributing to Better Health All Over the World
Slide 39: Future Outlook
國際委託研發暨生產服務(CDMO) 未來展望2021 • RYTARY 市場成長可期 • KCl客戶持續開發 Future Outlook • 北美業務開發團隊積極拓展訂單，並專注於增加大型生 技製藥客戶訂單 • 提升產能達成規模經濟 • 投入新產品線及研發 • 加拿大廠代工整合 經銷/代理 • 藥品與保健品銷售持續成長 – 瑞多寧拓展台灣與亞洲市場 – KCl ER拓展台灣市場 • 持續增加代理品項與經銷渠道布局 – 增加消費性產品品項 – 通路多元化
Slide 40: The Bora Advantage
The Bora Advantage International professional CDMO team Creating competitive efficiencies through scale Strong global customer base in a growing market Expanding with organic and inorganic Growth Focused on executing and delivering results
Slide 41: Contributing to Better Health All Over the World
Contributing to Better Health All Over the World